BioAtla's Key Clinical Presentation at SITC 2025
BioAtla, Inc. (NASDAQ: BCAB), an innovative biotechnology company, is preparing to present its latest findings on mecbotamab vedotin (BA3011), an AXL-targeting antibody-drug conjugate (ADC), at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. This event will occur from November 5 to 9, 2025.
Mecbotamab Vedotin in Focus
The clinical data that will be presented highlights significant outcomes for patients suffering from treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma. The presentation, titled "Median OS of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma treated with mecbotamab vedotin, an AXL-targeting ADC," aims to shed light on the potential of BA3011 as a transformative therapy.
Expert Insights from Dr. Mihaela Druta
Dr. Mihaela Druta from Moffitt Cancer Center will lead the presentation on November 7, 2025. This pivotal discussion will take place as part of a poster session at the conference, offering valuable insights into the efficacy and safety profile of the investigational drug.
Accessing Presentation Materials
Following the presentation, interested parties can access comprehensive materials regarding the findings on BioAtla's official website in the 'Publication' section. This resource will become available at the end of the presentation, providing deeper insights into the research.
Understanding BioAtla, Inc.
BioAtla is dedicated to developing novel therapeutics using its proprietary Conditionally Active Biologic (CAB) platform, which is designed to create antibodies with enhanced targeting and efficiency. With operations in both the U.S. and China, BioAtla is committed to advancing care in oncology through innovative treatment options. The company holds a robust patent portfolio that encompasses over 780 active patent matters, positioning itself as a leader in the biotechnology industry.
Future of Cancer Therapies
As BioAtla continues to push boundaries, their advancements in therapy development aim at making significant strides in treating various types of solid tumors, including sarcomas. The upcoming presentation at SITC 2025 is a testament to their commitment to innovation in cancer treatment.
Key Contacts at BioAtla
For further inquiries, Richard Waldron, Chief Financial Officer at BioAtla, can be contacted at 858.356.8945 or via email at rwaldron@bioatla.com. For external communications, Joyce Allaire with LifeSci Advisors is available for questions at jallaire@lifesciadvisors.com.
Frequently Asked Questions
What is mecbotamab vedotin?
Mecbotamab vedotin (BA3011) is an investigational antibody-drug conjugate developed by BioAtla targeting AXL to treat solid tumors.
When will the presentation of clinical data occur?
The presentation will take place on November 7, 2025, at the SITC Annual Meeting.
Who is delivering the presentation?
The presentation will be delivered by Dr. Mihaela Druta from Moffitt Cancer Center.
How can I access the presentation materials?
Presentation materials will be available in the 'Publication' section of BioAtla's website after the presentation concludes.
What is the significance of this research?
This research highlights essential advancements in the treatment of sarcomas, demonstrating the potential impact of mecbotamab vedotin on patient outcomes.
